First-ever RSV vaccine could be approved by August 2023, pending FDA review
Feb 23, 2023 10:22AM ● By Content Editor
Photo: FILE - A father cares for his 8-and-a-half-month-old son, who is in the intensive care unit of the pediatric clinic at a hospital with a respiratory infection. (Photo by Christoph Soeder/picture alliance via Getty Images)
By Kelly Hayes - Fox 9 News - February 23, 2023
By Kelly Hayes - Fox 9 News - February 23, 2023
The first-of-its-kind vaccine designed to protect infants from RSV, a common respiratory illness that can cause severe breathing problems, could be approved by August.
Pfizer, the maker behind the new RSV vaccine candidate referred to as RSVpreF, announced on Tuesday that the U.S. Food and Drug Administration had accepted its application for review and has set an action date of deciding whether to approve or not by August 2023.
To read the full story, visit the Fox 9 News site here.
